Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Insulin resistance and breast-cancer risk.

Bruning PF, Bonfrèr JM, van Noord PA, Hart AA, de Jong-Bakker M, Nooijen WJ.

Int J Cancer. 1992 Oct 21;52(4):511-6.

PMID:
1399128
2.

Body measurements, estrogen availability and the risk of human breast cancer: a case-control study.

Bruning PF, Bonfrèr JM, Hart AA, van Noord PA, van der Hoeven H, Collette HJ, Battermann JJ, de Jong-Bakker M, Nooijen WJ, de Waard F.

Int J Cancer. 1992 Apr 22;51(1):14-9.

PMID:
1563834
3.

Markers of insulin resistance and sex steroid hormone activity in relation to breast cancer risk: a prospective analysis of abdominal adiposity, sebum production, and hirsutism (Italy).

Muti P, Stanulla M, Micheli A, Krogh V, Freudenheim JL, Yang J, Schünemann HJ, Trevisan M, Berrino F.

Cancer Causes Control. 2000 Sep;11(8):721-30.

PMID:
11065009
5.

Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women.

Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE.

Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):161-4.

6.

Homeostasis model assessment to detect insulin resistance and identify patients at high risk of breast cancer development: National Cancer Institute of Naples experience.

Capasso I, Esposito E, Pentimalli F, Montella M, Crispo A, Maurea N, D'Aiuto M, Fucito A, Grimaldi M, Cavalcanti E, Esposito G, Brillante G, Lodato S, Pedicini T, D'Aiuto G, Ciliberto G, Giordano A.

J Exp Clin Cancer Res. 2013 Mar 14;32:14. doi: 10.1186/1756-9966-32-14.

7.
8.

Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Virgilio-Menopause-Health Group.

Pasquali R, Vicennati V, Bertazzo D, Casimirri F, Pascal G, Tortelli O, Labate AM.

Metabolism. 1997 Jan;46(1):5-9.

PMID:
9005961
9.

Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC).

Verheus M, Peeters PH, Rinaldi S, Dossus L, Biessy C, Olsen A, Tjønneland A, Overvad K, Jeppesen M, Clavel-Chapelon F, Téhard B, Nagel G, Linseisen J, Boeing H, Lahmann PH, Arvaniti A, Psaltopoulou T, Trichopoulou A, Palli D, Tumino R, Panico S, Sacerdote C, Sieri S, van Gils CH, Bueno-de-Mesquita BH, González CA, Ardanaz E, Larranaga N, Garcia CM, Navarro C, Quirós JR, Key T, Allen N, Bingham S, Khaw KT, Slimani N, Riboli E, Kaaks R.

Int J Cancer. 2006 Aug 1;119(3):659-67.

10.

Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer.

Bruning PF, Van Doorn J, Bonfrèr JM, Van Noord PA, Korse CM, Linders TC, Hart AA.

Int J Cancer. 1995 Jul 28;62(3):266-70. Erratum in: Int J Cancer 1995 Nov 27;63(5):762.

PMID:
7543079
11.

The quantitative relationship between "the metabolic syndrome" and abdominal obesity in women.

Lapidus L, Bengtsson C, Björntorp P.

Obes Res. 1994 Jul;2(4):372-7.

12.

Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience.

Capasso I, Esposito E, Pentimalli F, Crispo A, Montella M, Grimaldi M, De Marco M, Cavalcanti E, D'Aiuto M, Fucito A, Frasci G, Maurea N, Esposito G, Pedicini T, Vecchione A, D'Aiuto G, Giordano A.

Cancer Biol Ther. 2010 Dec 15;10(12):1240-3. Epub 2010 Dec 15.

PMID:
20935521
13.

Hyperinsulinemia in patients with coronary heart disease in absence of overt risk factors.

Ariza CR, Frati AC, Gómez G, Almazán A.

Arch Med Res. 1997 Spring;28(1):115-9.

PMID:
9078598
14.

Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women.

Schairer C, Hill D, Sturgeon SR, Fears T, Pollak M, Mies C, Ziegler RG, Hoover RN, Sherman ME.

Int J Cancer. 2004 Feb 20;108(5):773-9.

15.

Fasting glucose is a risk factor for breast cancer: a prospective study.

Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schünemann HJ, Ram M, Freudenheim JL, Sieri S, Trevisan M, Berrino F.

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1361-8.

16.

Population-based, case-control study of blood C-peptide level and breast cancer risk.

Yang G, Lu G, Jin F, Dai Q, Best R, Shu XO, Chen JR, Pan XY, Shrubsole M, Zheng W.

Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1207-11.

17.

Central adiposity after breast cancer diagnosis is related to mortality in the Health, Eating, Activity, and Lifestyle study.

George SM, Bernstein L, Smith AW, Neuhouser ML, Baumgartner KB, Baumgartner RN, Ballard-Barbash R.

Breast Cancer Res Treat. 2014 Aug;146(3):647-55. doi: 10.1007/s10549-014-3048-x. Epub 2014 Jul 24.

PMID:
25056184
18.

A prospective study of plasma C-peptide and colorectal cancer risk in men.

Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, Stampfer MJ.

J Natl Cancer Inst. 2004 Apr 7;96(7):546-53.

PMID:
15069117
19.
20.

Diabetes and risk of breast cancer in Asian-American women.

Wu AH, Yu MC, Tseng CC, Stanczyk FZ, Pike MC.

Carcinogenesis. 2007 Jul;28(7):1561-6. Epub 2007 Apr 17.

PMID:
17440036

Supplemental Content

Support Center